>
Switch to:

Biogen Earnings Yield (Joel Greenblatt) %

: 4.15% (As of Sep. 2021)
View and export this data going back to 1991. Start your Free Trial

Biogen's Enterprise Value for the quarter that ended in Sep. 2021 was $46,687 Mil. Biogen's EBIT for the trailing twelve months (TTM) ended in Sep. 2021 was $1,937 Mil. Biogen's Earnings Yield (Joel Greenblatt) for the quarter that ended in Sep. 2021 was 4.15%.

The historical rank and industry rank for Biogen's Earnings Yield (Joel Greenblatt) % or its related term are showing as below:

NAS:BIIB' s Earnings Yield (Joel Greenblatt) % Range Over the Past 10 Years
Min: 3.33   Med: 7.69   Max: 16.51
Current: 4.37

3.33
16.51

During the past 13 years, the highest Earnings Yield (Joel Greenblatt) of Biogen was 16.51%. The lowest was 3.33%. And the median was 7.69%.

NAS:BIIB's Earnings Yield (Joel Greenblatt) % is ranked higher than
63% of the 146 Companies
in the Drug Manufacturers industry.

( Industry Median: -3.65 vs. NAS:BIIB: 4.37 )

Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.

A better indicator of the attractiveness of an investment which takes growth into account is the Forward Rate of Return (Yacktman) %. Biogen's Forward Rate of Return (Yacktman) % for the quarter that ended in Sep. 2021 was 11.53%. The Forward Rate of Return uses the normalized Free Cash Flow of the past seven years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.


Biogen Earnings Yield (Joel Greenblatt) % Historical Data

The historical data trend for Biogen's Earnings Yield (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biogen Annual Data
Trend Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20
Earnings Yield (Joel Greenblatt) %
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 8.95 7.73 9.88 13.64 12.39

Biogen Quarterly Data
Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21
Earnings Yield (Joel Greenblatt) % Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 13.85 12.39 8.59 4.58 4.15

Competitive Comparison

For the Drug Manufacturers - General subindustry, Biogen's Earnings Yield (Joel Greenblatt) %, along with its competitors' market caps and Earnings Yield (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

   

Biogen Earnings Yield (Joel Greenblatt) % Distribution

For the Drug Manufacturers industry and Healthcare sector, Biogen's Earnings Yield (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where Biogen's Earnings Yield (Joel Greenblatt) % falls into.



Biogen Earnings Yield (Joel Greenblatt) % Calculation

In his book, The Little That Beat the Market, hedge fund manager Joel Greenblatt defines Earnings Yield as operating income divided by enterprise value.

Biogens Earnings Yield (Joel Greenblatt) for the fiscal year that ended in Dec. 2020 is calculated as

Earnings Yield (Joel Greenblatt)=EBIT/Enterprise Value
=5270/42520.564
=12.39 %

Biogen's EBIT for the trailing twelve months (TTM) ended in Sep. 2021 adds up the quarterly data reported by the company within the most recent 12 months, which was $1,937 Mil.



Biogen  (NAS:BIIB) Earnings Yield (Joel Greenblatt) % Explanation

Joel Greenblatt defines the earnings yield using the above equation because it more accurately reflects the company's profitability relative to its stock price. Items like interest payment and tax etc. are not directly related to the company's operational profitability.

Enterprise Value instead of market cap (share price) is used in the calculation because it is the real price stock and bond investors together pay for the company.


Be Aware

Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.

Forward Rate of Return (Yacktman) % based on Don Yacktman's definition is a better measure of the expected rate of return for a stock.


Biogen Earnings Yield (Joel Greenblatt) % Related Terms

Thank you for viewing the detailed overview of Biogen's Earnings Yield (Joel Greenblatt) % provided by GuruFocus.com. Please click on the following links to see related term pages.


Biogen Business Description

Biogen logo
Industry
Healthcare » Drug Manufacturers NAICS : 325412 SIC : 2834
Address
225 Binney Street, Cambridge, MA, USA, 02142
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Executives
Mcdonnell Michael R officer: EVP, Chief Financial Officer C/O IQVIA HOLDINGS INC. 83 WOOSTER HEIGHTS ROAD DANBURY CT 06810
Gregory Ginger officer: EVP, Human Resources C/O BIOGEN INC. 225 BINNEY ST. CAMBRIDGE MA 02142
Kramer Robin officer: VP, Chief Accounting Officer 999 VANDERBILT BEACH ROAD 3RD FLOOR NAPLES FL 34109
Sherwin Stephen A director C/O CELL GENESYS, INC. 500 FORBES BLVD. SOUTH SAN FRANCISCO CA 94080
Hawkins William A director MEDTRONIC INC 710 MEDTRONIC PKWY, MS LC310 MINNEAPOLIS MN 55432-5604
Dorsa Caroline director BIOGEN INC. 225 BINNEY ST. CAMBRIDGE MA 02142
Papadopoulos Stelios director 3 SOMERSET DRIVE SOUTH GREAT NECK NY 11020
Pangia Robert W director 3965 FREEDOM CIRCLE SANTA CLARA CA 95054
Leaming Nancy director C/O HOLOGIC INC BEDFORD MA 01730
Rowinsky Eric K director IMCLONE SYSTEMS INCORPORATED 180 VARICK STREET, 6TH FLOOR NEW YORK NY 10014
Denner Alexander J director C/O SARISSA CAPITAL MANAGEMENT LP 660 STEAMBOAT ROAD, 3RD FLOOR GREENWICH CT 06830
Posner Brian S director 14 CAMBRIDGE CENTER CAMBRIDGE MA 02142
Mulligan Richard director C/O ICAHN CAPITAL LP 767 FIFTH AVENUE, SUITE 4700 NEW YORK NY 10153
Mantas Jesus B director BIOGEN INC. 225 BINNEY STREET CAMBRIDGE MA 02142
Galdes Alphonse officer: EVP Pharmaceutical Oper & Tech BIOGEN INC. 225 BINNEY ST. CAMBRIDGE MA 02142

Biogen Headlines

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)